Osiris Therapeutics, Inc.
http://www.osiris.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Osiris Therapeutics, Inc.
Keeping Up The Pressure In Pulmonary Arterial Hypertension
Merck & Co leads a market expected to exceed $10bn by 2028, but others are aiming to muscle in.
Exscientia Focus Firmly On Pipeline After CEO Exit Scandal
The sacking of CEO Andrew Hopkins over inappropriate relationships with two employees has cast a cloud over the high-profile AI biotech.
Confirmatory Trials: Flexibility In Timing Hinges On Accelerated Approval Indication Size – FDA’s Marks
CBER director suggests more flexibility on confirmatory study timing is warranted for accelerated approvals in rare diseases and even in some more common scenarios such as infectious disease outbreaks, although a ‘relatively stronger approach’ will apply to most large indications.
Finance Watch: Two Biopharma IPOs Bring US Total To 17
Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice